The brief explains that adaptive trial designs can improve clinical and operational outcomes but adoption is limited because benefits are hard to quantify. IQVIA proposes using the expected Net Present Value (eNPV) metric, which integrates time, cost, risk and revenue to compare trial design options and programs. eNPV uses activity‑based benchmarks and risk‑adjusted calculations to estimate timelines and costs, helping planners choose designs that maximise probability of success and return on investment. Technology platforms like IQVIA’s Pipeline Architect automate this analysis.

Join for free to read